|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Zhang S, Zhao P, Zeng H,
Zou X and He J: Annual report on status of cancer in China, 2010.
Chin J Cancer Res. 26:48–58. 2014.PubMed/NCBI
|
|
3
|
Brenner H, Kloor M and Pox CP: Colorectal
cancer. Lancet. 383:1490–1502. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Halasi M and Gartel AL: Targeting FOXM1 in
cancer. Biochem Pharmacol. 85:644–652. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Alvarez-Fernandez M and Medema RH: Novel
functions of FoxM1: From molecular mechanisms to cancer therapy.
Front Oncol. 3:302013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pilarsky C, Wenzig M, Specht T, Saeger HD
and Grützmann R: Identification and validation of commonly
overexpressed genes in solid tumors by comparison of microarray
data. Neoplasia. 6:744–750. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Christensen L, Joo J, Lee S, Wai D, Triche
TJ and May WA: FOXM1 is an oncogenic mediator in Ewing Sarcoma.
PloS One. 8:e545562013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yoshida Y, Wang IC, Yoder HM, Davidson NO
and Costa RH: The forkhead box M1 transcription factor contributes
to the development and growth of mouse colorectal cancer.
Gastroenterology. 132:1420–1431. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schwencke C, Braun-Dullaeus RC, Wunderlich
C and Strasser RH: Caveolae and caveolin in transmembrane
signaling: Implications for human disease. Cardiovasc Res.
70:42–49. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Quest AF, Gutierrez-Pajares JL and Torres
VA: Caveolin-1: An ambiguous partner in cell signalling and cancer.
J Cell Mol Med. 12:1130–1150. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kannan A, Krishnan A, Ali M, Subramaniam
S, Halagowder D and Sivasithamparam ND: Caveolin-1 promotes gastric
cancer progression by up-regulating epithelial to mesenchymal
transition by crosstalk of signalling mechanisms under hypoxic
condition. Eur J Cancer. 50:204–215. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bender FC, Reymond MA, Bron C and Quest
AF: Caveolin-1 levels are down-regulated in human colon tumors, and
ectopic expression of caveolin-1 in colon carcinoma cell lines
reduces cell tumorigenicity. Cancer Res. 60:5870–5878.
2000.PubMed/NCBI
|
|
13
|
Fine SW, Lisanti MP, Galbiati F and Li M:
Elevated expression of caveolin-1 in adenocarcinoma of the colon.
Am J Clin Pathol. 115:719–724. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gumbiner BM: Regulation of
cadherin-mediated adhesion in morphogenesis. Nat Rev Mol Cell Biol.
6:622–634. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Huang C, Qiu Z, Wang L, Peng Z, Jia Z,
Logsdon CD, Le X, Wei D, Huang S and Xie K: A novel FoxM1-caveolin
signaling pathway promotes pancreatic cancer invasion and
metastasis. Cancer Res. 72:655–665. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kong FF, Qu ZQ, Yuan HH, Wang JY, Zhao M,
Guo YH, Shi J, Gong XD, Zhu YL, Liu F, et al: Overexpression of
FOXM1 is associated with EMT and is a predictor of poor prognosis
in non-small cell lung cancer. Oncol Rep. 31:2660–2668.
2014.PubMed/NCBI
|
|
17
|
He X, Chen Z, Jia M and Zhao X:
Downregulated E-cadherin expression indicates worse prognosis in
Asian patients with colorectal cancer: Evidence from meta-analysis.
PloS One. 8:e708582013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Edge S, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: AJCC Cancer Staging Manual. 7th. Springer;
NY: 2010
|
|
19
|
Huang C, Du J and Xie K: FOXM1 and its
oncogenic signaling in pancreatic cancer pathogenesis. Biochim
Biophys Acta. 1845:104–116. 2014.PubMed/NCBI
|
|
20
|
Lam EWF, Brosens JJ, Gomes AR and Koo CY:
Forkhead box proteins: Tuning forks for transcriptional harmony.
Nat Rev Cancer. 13:482–495. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Miao L, Xiong X, Lin Y, Cheng Y, Lu J,
Zhang J and Cheng N: Down-regulation of FoxM1 leads to the
inhibition of the epithelial-mesenchymal transition in gastric
cancer cells. Cancer Genet. 207:75–82. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Takata A, Takiguchi S, Okada K, Takahashi
T, Kurokawa Y, Yamasaki M, Miyata H, Nakajima K, Mori M and Doki Y:
Clinicopathological and prognostic significance of FOXM1 expression
in esophageal squamous cell carcinoma. Anticancer Res.
34:2427–2432. 2014.PubMed/NCBI
|
|
23
|
Li D, Wei P, Peng Z, Huang C, Tang H, Jia
Z, Cui J, Le X, Huang S and Xie K: The critical role of
dysregulated FOXM1-PLAUR signaling in human colon cancer
progression and metastasis. Clin Cancer Res. 19:62–72. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Huang C, Xie D, Cui J, Li Q, Gao Y and Xie
K: FOXM1c promotes pancreatic cancer epithelial-to-mesenchymal
transition and metastasis via upregulation of expression of the
urokinase plasminogen activator system. Clin Cancer Res.
20:1477–1488. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yang C, Chen H, Tan G, Gao W, Cheng L,
Jiang X, Yu L and Tan Y: FOXM1 promotes the epithelial to
mesenchymal transition by stimulating the transcription of Slug in
human breast cancer. Cancer Lett. 340:104–112. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wierstra I: The transcription factor
FOXM1c binds to and transactivates the promoter of the tumor
suppressor gene E-cadherin. Cell Cycle. 10:760–766. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Williams TM and Lisanti MP: The caveolin
proteins. Genome Biol. 5:2142004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sanna E, Miotti S, Mazzi M, De Santis G,
Canevari S and Tomassetti A: Binding of nuclear caveolin-1 to
promoter elements of growth-associated genes in ovarian carcinoma
cells. Exp Cell Res. 313:1307–1317. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Martins D, Beça FF, Sousa B, Baltazar F,
Paredes J and Schmitt F: Loss of caveolin-1 and gain of MCT4
expression in the tumor stroma: Key events in the progression from
an in situ to an invasive breast carcinoma. Cell Cycle.
12:2684–2690. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Müller R, Gai X, Lu Z, Tu K, Liang Z and
Zheng X: Caveolin-1 Is up-regulated by GLI1 and contributes to
GLI1-driven EMT in hepatocellular carcinoma. PloS one.
9:e845512014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liang W, Hao Z, Han JL, Zhu DJ, Jin ZF and
Xie WL: CAV-1 contributes to bladder cancer progression by inducing
epithelial-to-mesenchymal transition. Urologic Oncol. 32:855–863.
2014. View Article : Google Scholar
|
|
32
|
Nimri L, Barak H, Graeve L and Schwartz B:
Restoration of caveolin-1 expression suppresses growth,
membrane-type-4 metalloproteinase expression and
metastasis-associated activities in colon cancer cells. Mol
Carcinog. 52:859–870. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Patlolla JM, Swamy MV, Raju J and Rao CV:
Overexpression of caveolin-1 in experimental colon adenocarcinomas
and human colon cancer cell lines. Oncol Rep. 11:957–963.
2004.PubMed/NCBI
|
|
34
|
Ha TK, Her NG, Lee MG, Ryu BK, Lee JH, Han
J, Jeong SI, Kang MJ, Kim NH, Kim HJ, et al: Caveolin-1 increases
aerobic glycolysis in colorectal cancers by stimulating
HMGA1-mediated GLUT3 transcription. Cancer Res. 72:4097–4109. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gao J, Zhu Y, Nilsson M and Sundfeldt K:
TGF-b isoforms induce EMT independent migration of ovarian cancer
cells. Cancer Cell Int. 14:722014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang J, Xu L, Yang Z, Lu H, Hu D, Li W,
Zhang Z, Liu B and Ma S: MicroRNA-10b indicates a poor prognosis of
non-small cell lung cancer and targets E-cadherin. Clin Transl
Oncol. 17:209–214. 2015. View Article : Google Scholar : PubMed/NCBI
|
